MetrioPharm Press Releases
-
MetrioPharm Enrolls Last Patient in Phase II Study on MP1032 in Psoriasis
MetrioPharm AG announces that it has enrolled the last patient with moderate-to-severe plaque psoriasis in its ongoing Phase II clinical trial.
-
Dr. Wolfgang Brysch, CEO of MetrioPharm AG, is a speaker on the panel Autoimmune and Inflammatory Diseases on February 25th
MetrioPharm AG announces that its CEO Dr. Wolfgang Brysch will participate in the 12th Annual European Life Science CEO Forum.
-
MetrioPharm AG Closes Financing Round of CHF 20 Million
MetrioPharm closes Private Equity Financing Round D. Funds to be used for ongoing Phase II study and a Phase IIa study in an additional indication.
-
MetrioPharm AG Expands Patent Protection for its Lead Compound MP1032 to Canada
MetrioPharm AG announces that a substance patent for its lead compound MP1032 has been obtained in Canada. The Canadian patent CA 2791327 was granted on October 30, 2018.
-
MetrioPharm Announces Presentation of Preclinical Data on MP1032 in Multiple Sclerosis Therapy at ECTRIMS Congress 2018
MetrioPharm AG announces the presentation of preclinical data related to multiple sclerosis (MS) and the company’s lead-compound MP1032 at the 34th ECTRIMS Congress.
-
MetrioPharm Achieves 50% of Target Patients Randomized in MP1032 Phase II Clinical Trial
MetrioPharm AG, today announced that more than 50% of patients with moderate-to-severe psoriasis (PASI entry score 10-20) have been randomized in the company’s ongoing Phase II clinical trial.
-
MetrioPharm Presents Clinical Phase IIa Psoriasis Study Data at the 5th WPPAC in Stockholm
MetrioPharm AG announced that clinical Phase IIa data obtained from patients with moderate to severe plaque psoriasis will be presented at the 5th World Psoriasis & Psoriatic Arthritis Conference (WPPAC) in Stockholm.
-
Data Presentation on the Mechanism of Action of MP1032
MetrioPharm Announces Data Presentation on the Mechanism of Action of MP1032 at the 19th SFRRI Meeting in Lisbon
-
MetrioPharm announces first patient dosed in a clinical phase II trial for MP1032 for the treatment of moderate-to-severe chronic plaque psoriasis
Zurich, March 07, 2018. MetrioPharm AG announces the first dosing of the first patient in its phase II clinical trial MP1032-CT04 on March 06, 2018.
-
MetrioPharm AG Expands Patent Protection for its Lead Compound MP1032 to South Korea
Zurich, September 07, 2017. MetrioPharm AG announces that a basic patent has been granted on its lead compound MP1032 in South Korea.